<DOC>
	<DOCNO>NCT02829996</DOCNO>
	<brief_summary>Phase II , randomize , double-masked study evaluate efficacy tolerability topical ocular delivery fixed-dosed combination trabodenoson latanoprost subject Ocular Hypertension Primary Open-Angle Glaucoma . All subject meet study 's enrollment criterion follow Screening undergo washout prohibit medication ( washout need ) , include routine glaucoma medication . During Placebo Run-In Period , placebo apply twice daily eye subject . During Treatment Period , study drug apply eye total 8 week . Each subject assign 4 week AM 4 week PM dose masked manner . AM vs PM dosing mask utilizing Placebo addition active drug product . During Treatment Period , study drug ( Active Placebo ) eye drop application occur twice daily , morning evening . The Treatment Period follow Observation Period approximately 7 day wherein study eye drop instill . The purpose study ass overall benefit/risk profile binocular topical application different dos trabodenoson ( 3.0 % 6.0 % ) combine latanoprost ( 0.005 % 0.0025 % ) one drop daily ( QD ) 8 week .</brief_summary>
	<brief_title>Study Fixed-Dose Combinations Trabodenoson Latanoprost Adults With Ocular Hypertension Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis ocular hypertension ( OHT ) primary openangle glaucoma ( POAG ) Mean Intraocular pressure ( IOP ) ≥25 ≤34 Significant visual field loss new field loss within past year Cuptodisc ratio &gt; 0.8 Central corneal thickness &lt; 490 µm &gt; 610 µm A recent ( acute ) chronic medical condition might obfuscate Subject 's study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>primary open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>adenosine agonist</keyword>
	<keyword>eye drop</keyword>
	<keyword>trabodenoson</keyword>
	<keyword>trabecular meshwork</keyword>
</DOC>